Session Information
Date: Thursday, June 23, 2016
Session Title: Parkinson's disease: Clinical trials, pharmacology and treatment
Session Time: 12:00pm-1:30pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: To investigate the association between dopamine receptor D types 2(DRD2) (CA)n and types 3 (DRD3) Ser9Gly polymorphisms and the risk of Parkinson’s disease (PD), as well as response to dopamine agonists(DAs).
Background: Levodopa and DAs are the key medications applied to treat PD. Currently; it is thought that genetic variations in the gene encoding the DAs are an important factor in determining inter-individual variability in drug response. Of which, DRD2 (CA)n and DRD3 Ser9Gly polymorphisms are extensively investigated.
Methods: 123 idiopathic PD patients and 129 healthy individuals were included in this study. Clinical features of PD patients were collected, consisting of the age of onset, disease duration, the H&Y stage, LED, total doses of DAs, including Pramipexole and Peribedil,UPDRS, NMS-Quest, HAMA, HAMD and MMSE. Statistical analysis was carried out to find the genotype and allele frequencies distribution between PD patients and controls. We also assessed its association with clinical features in PD patients.
Results: 1. There were no significant difference in DRD2 (CA)n and DRD3 Ser9Gly genotype (P=0.21, P=0.55), or in allele frequencies (P=0.13, P=0.78) between PD patients and controls. 2. In PD patients, there were 57 people taking DAs (Pramipexole: n=33 and Peribedil: n=24). Based on whether combined application of Levodopa, we further divided the patients into two groups: single DAs group (n=10); Levodopa and DAs group (n=47). Among DRD3 Ser9Gly different genotypes (Ser/Ser, Ser/Gly, Gly/Gly), no significant difference were found in clinical features. However, patients with Gly/Gly genotype used higher doses of DAs than Ser/Ser and Ser/Gly group, whether in single DAs group (P=0.01) or in Levodopa and DAs group (P=0.03), even in the entire DAs group (P=0.002). And the difference was mostly due to the higher use of Pramipexole rather than Peribedil. As to DRD2 (CA)n polymorphism, there was no significant association between the different genotypes and response to DAs.
Conclusions: Our study showed that DRD2 (CA)n and DRD3 Ser9Gly polymorphism might not be associated with risk of PD. DRD3 Ser9Gly polymorphism are associated with the dosage of Pramipexole in Chinese PD patients. And large-scale and multi-center studies are needed to evaluate the impact of the genetic variations on the individual difference to dopamine agonists.
To cite this abstract in AMA style:
S. Xu, J. Liu, X. Yang, Y. Qian, Q. Xiao. Association of the DRD2 (CA) n and DRD3 Ser9Gly polymorphisms with Parkinson’s disease and response of dopamine agonists [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/association-of-the-drd2-ca-n-and-drd3-ser9gly-polymorphisms-with-parkinsons-disease-and-response-of-dopamine-agonists/. Accessed May 21, 2025.« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/association-of-the-drd2-ca-n-and-drd3-ser9gly-polymorphisms-with-parkinsons-disease-and-response-of-dopamine-agonists/